FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least 2 oral antidepressants, according to a news release issued by Johnson & Johnson.
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...
"SPRAVATO ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback